State of Alaska Department of Revenue Has $2.42 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

State of Alaska Department of Revenue reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 28.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,082 shares of the life sciences company's stock after selling 7,345 shares during the period. State of Alaska Department of Revenue's holdings in Illumina were worth $2,416,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Bleakley Financial Group LLC acquired a new position in Illumina during the fourth quarter worth about $751,000. Capital Investment Services of America Inc. boosted its position in shares of Illumina by 2.0% in the 4th quarter. Capital Investment Services of America Inc. now owns 84,617 shares of the life sciences company's stock valued at $11,307,000 after purchasing an additional 1,651 shares during the period. Stratos Wealth Partners LTD. boosted its position in shares of Illumina by 2.5% in the 4th quarter. Stratos Wealth Partners LTD. now owns 6,534 shares of the life sciences company's stock valued at $873,000 after purchasing an additional 160 shares during the period. E. Ohman J or Asset Management AB boosted its position in shares of Illumina by 7.7% in the 4th quarter. E. Ohman J or Asset Management AB now owns 6,965 shares of the life sciences company's stock valued at $931,000 after purchasing an additional 500 shares during the period. Finally, Mather Group LLC. boosted its position in shares of Illumina by 432.5% in the 4th quarter. Mather Group LLC. now owns 820 shares of the life sciences company's stock valued at $110,000 after purchasing an additional 666 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 1.5 %

Shares of ILMN traded down $1.54 during midday trading on Friday, reaching $100.24. 3,135,782 shares of the stock were exchanged, compared to its average volume of 2,405,156. Illumina, Inc. has a 12-month low of $99.35 and a 12-month high of $156.66. The firm has a 50 day simple moving average of $133.56 and a 200-day simple moving average of $134.88. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a market cap of $15.90 billion, a price-to-earnings ratio of -13.05 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Research analysts forecast that Illumina, Inc. will post 4.42 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ILMN. Stephens increased their price target on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Robert W. Baird increased their price target on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and decreased their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised their price objective on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.